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Prevalence of Human Papilloma Virus Infections and Cervical 
Cytological Abnormalities among Korean Women with Systemic 
Lupus Erythematosus
We performed a multicenter cross-sectional study of 134 sexually active systemic lupus 
erythematosus (SLE) patients to investigate the prevalence of and risk factors for high risk 
human papilloma virus (HPV) infection and cervical cytological abnormalities among 
Korean women with SLE. In this multicenter cross-sectional study, HPV testing and routine 
cervical cytologic examination was performed. HPV was typed using a hybrid method or 
the polymerase chain reaction. Data on 4,595 healthy women were used for comparison. 
SLE patients had greater prevalence of high-risk HPV infection (24.6% vs. 7.9%, P<0.001, 
odds ratio 3.8, 95% confidence interval 2.5-5.7) and of abnormal cervical cytology (16.4 vs. 
2.8%, P<0.001, OR 4.4, 95% CI 2.5-7.8) compared with controls. SLE itself was identified as 
independent risk factors for high risk HPV infection among Korean women (OR 3.8, 95% CI 
2.5-5.7) along with ≥2 sexual partners (OR 8.5, 95% CI 1.2-61.6), and Pap smear 
abnormalities (OR 97.3, 95% CI 6.5-1,456.7). High-risk HPV infection and cervical 
cytological abnormalities were more common among Korean women with SLE than 
controls. SLE itself may be a risk factor for HPV infection among Korean women, suggesting 
the importance of close monitoring of HPV infections and abnormal Pap smears in SLE 
patients.   
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INTRODUCTION
Human papillomavirus (HPV) infection is thought to be princi-
ple causal agent for cervical cancer worldwide (1). In particular, 
persistent infection with high-cancer-risk HPV type 16 and 18 is 
major risk factor for cervical cancer (2). In the case of immuno-
compromised host, the risk of HPV infection was reported to be 
much greater than the general population due to high-load, per-
sistent infection with oncogenic HPV genotypes (3-6). The prev-
alence of HPV infection was shown to increase in organ trans-
plant recipients (3, 7), human immunodeficiency virus (HIV)-
infected women (4-6), and patients with systemic autoimmune 
diseases such as systemic lupus erythematosus (SLE) (8, 9).
  Since SLE is a multi-system disease characterized by produc-
tion of a vast array of autoantibodies against multiple tissues 
and organs, multiple factors including genetic and ethnic back-
ground, immunological abnormalities, extent of organ damage, 
and behavioral patterns might account for the increased sus-Lee Y-H, et al.  •  HPV Infections in Korean SLE Patients
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ceptibility of SLE patients to HPV infection and cervical cancer. 
The socioeconomic impact of the increased risk of cervical can-
cer in Korean patients with SLE can be greater since it is known 
that there is an increase in prevalence of SLE in the Asian popu-
lation (10). However, there is a paucity of data regarding the prev-
alence of high risk HPV infection and cervical cytological ab-
normalities in SLE patients of different ethnic background and 
regions. Moreover, disease related risk factors for HPV infections 
in SLE patients remain unclear. The purpose of our study was to 
investigate the prevalence of and risk factors for HPV infection, 
and cervical cytological abnormalities in Korean patients with 
SLE. 
MATERIALS AND METHODS
Patients
All patients attending the rheumatology clinic at 7 tertiary hos-
pitals in Korea who fulfilled the 1997 American College of Rheu-
matology (ACR) criteria for SLE were invited to participate in 
this cross-sectional study. Participating hospitals were located 
throughout Korea including Seoul, Gyeonggi-do, Gyeongsang-
do, and Jeolla-do regions including both urban and rural areas.  
Patients were eligible for the study if they had been sexually ac-
tive. Patients who never had sexual intercourse and patients 
younger than 20 yr old were excluded. One hundred thirty four 
SLE patients who signed the informed consent out of total 1525 
SLE patients were recruited between February 2006 and March 
2007 through a survey in clinic. The study was approved by the 
local ethics committee of each institution. For comparison, data 
from a cross-sectional study of women attending the National 
Cervical Cancer Screening Program carried out by Oh et al. (11) 
on prevalence of HPV infection of 4595 women in Busan and 
Suwon, Korea were used. Women attending the National Cervi-
cal Cancer Screening Program belonged to mostly low income 
social groups who visited government affiliated hospitals in both 
urban and rural areas. The data was supplemented by 113 wom-
en aged 20-29 yr who visited local hospital for routine gyneco-
logic care, since the National Cervical Cancer Screening Pro-
gram included mostly women over 30 yr of age.
Clinical data collection
Patient interviews and chart reviews were performed at the time 
of the enrollment to obtain information regarding sexual be-
haviors, obstetric and gynecological histories, and disease his-
tory related to SLE. We obtained demographic information in-
cluding age, marital status, duration of education, and tobacco 
smoking, and reproductive and sexual history including num-
ber of gestations and parity, age at first intercourse, number of 
sexual partners, and history of sexually transmitted diseases. 
Disease history related to SLE included disease duration, extent 
of organ involvement, and type of treatment received. Major 
organ involvement was defined as involvement of one or more 
of the following organs: the central nervous system, lung, heart, 
kidney, intestine, and the hematologic system (hemolytic ane-
mia, platelet <100,000/μL). Treatment with prednisolone >1 mg/ 
kg/day, azathioprine, cyclosporine, mycophenolate mofetil and/ 
or cyclophosphamide was defined as immunosuppressive ther-
apy. Autoantibodies including antinuclear antibody (ANA), an-
ti-double strand DNA (dsDNA), and systemic lupus erythema-
tosus disease activity index (SLEDAI) were assessed at the time 
of gynecological evaluation. 
Gynecological examination and specimen collection 
All patients underwent gynecologic examinations, which in-
cluded HPV testing and Pap smears, by gynecologists at each 
hospital. HPV DNA tests were performed on exfoliated cervical 
cells and examined by either Hybrid Capture II (HC-II) tech-
nology (The digene HPV test, Gaithersburg, MD, USA) which 
detected 13 high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, 68) or a polymerase chain reaction (PCR) based DNA 
microarray system (My HPV chip, Mygene, Seoul, Korea), which 
detect 16 types of high-risk HPV (16, 18, 31, 33, 35, 39, 45, 51, 52, 
53, 54, 56, 58, 59, 66, 68) and 8 types of low-risk HPV (6, 11, 34, 
40, 42, 43, 44, 70). Five of the 7 participating centers utilize the 
Hybrid Capture II technology and 2 utilized the PCR based DNA 
microarray system. The Hybrid Capture II technology system 
was used for the community control. Both HC-II and microar-
rays were highly comparable in terms of sensitivity, specificity, 
and positive and negative predictive values for detecting HPV 
in cervical specimens (12). To perform hybrid capture technol-
ogy, cervical specimens were combined with an extraction buf-
fer to release and denature the HPV DNA. The released DNAs 
were combined with specific RNA probes to create the RNA-
DNA hybrids, which were captured on a solid phase by an anti-
body specific for the hybrids. The captured RNA-DNA hybrids 
were tagged with antibody reagent, and measured using a lumi-
nometer. To perform PCR based DNA microarrays, target HPV 
DNA from cervical specimens were amplified by PCR using the 
primers of MY09/MY11 (5´-CGTCCMARRGGAWACTGATC-
3´/5´-GCMCAGGGWCATAAYAATGG-3´) and GP5+/GP6+(5´-
TTTGTTACTGTGGTAGATACTAC-3´/5´-Cy3-GAAAAATAAA-
CTGTAAATCATATTC-3´). Primers that amplify β-globin were 
used as controls (5´-Cy3-CAACTTCATCCACGTTCACC-3´/5´-
GAAGAGCCAAGGACAGGTAC-3´). The PCR product was hy-
bridized onto the chip at 42°C for 4 hr and washed with buffer. 
Hybridized signals were visualized with a DNA chip scanner. If 
the binding of a high-risk HPV subtype was detected in hybrid 
capture and microarray tests, it was considered positive for HPV. 
In case of an abnormal Pap results, a histological examination 
was done. The interval between Pap smear and histological ex-
amination was less than 1 month. Lee Y-H, et al.  •  HPV Infections in Korean SLE Patients
http://jkms.org   1433 DOI: 10.3346/jkms.2010.25.10.1431
Statistical analysis 
Clinical parameters are presented as mean±SD. Comparisons 
between the SLE patients and the controls were analyzed using 
the χ2-test. Odds ratios (ORs) with 95% confidence intervals (CIs) 
were used to estimate the association between each possible 
risk factor and HPV infection in SLE patients. Independent risk 
factors for HPV infection in SLE patients were determined using 
a multiple logistic regression equation. Statistical analysis was 
done using SPSS 12.0 (SPSS Inc, Chicago, IL, USA) software. 
Ethics statement
The study was conducted according to the protocols approved 
by the institutional ethics committee of each institution in com-
pliance with the Helsinki Declaration (IRB approval numbers: 
Ewha Womans University Mokdong Hospital; ECT 125-5, Daegu 
Catholic University Medical Center; CR-06-22-83, Chonnam 
National University Hospital; 06-nuh, Kyungpook National Uni-
versity Hospital; 7405-1929-2009.07.07, Inha University Hospi-
tal; 2006-580, Hanyang University Medical Center; 2006-29, Ajou 
University Hopital; AJIRB-CRO-06-109).
RESULTS
Characteristics of patients and controls 
SLE patients and controls were all ethnically Koreans and de-
mographically similar coming from both rural and urban areas, 
except that SLE patients included younger age group. The mean 
age of SLE patients was 39.5±9.4 (mean±SD) yr. Individuals 
younger than 39 yr of age accounted for 55.9% of the patient 
group, whereas 16.0% in the controls. Reproductive and behav-
ioral characteristics between SLE patients and healthy controls 
were also similar with the exception of parity. SLE patients show-
ed a significantly lower number of parity compared with the con-
trols. The mean disease duration of SLE patients was 51.2±43.2 
months. Major organs were involved in 89 (66.4%) patients, and 
in 26 (19.4%) patients, two or more multiple major organs were 
involved. Drug exposures ever during the course of lupus up to 
the present are as shown in Table 1. Immunosuppressive agents 
including prednisolone ≥1 mg/kg/day, azathioprine, cyclospo-
rine, mycophenolate mofetil, and cyclophosphamide were pre-
scribed for 97 (72.4%) patients. All patients were ANA positive 
and the mean titer was 1:360. Anti-dsDNA was observ  ed in 92 
(68.7%) of patients, and the mean titer was 62.5 IU/mL. SLEDAI 
at the time of gynecologic evaluation was 8.1±6.4 (Table 1). 
Prevalence of HPV infection and abnormal cytology in 
SLE patients 
Infection with a high-risk type of HPV was detected in 33 (24.6%), 
and abnormal Pap smears were observed in 22 (16.4%) of SLE 
patients. Abnormal Pap smear results included epithelial dys-
plasia in 8 patients, atypical squamous cells of undetermined 
significance (ASCUS) in 7 patients, and carcinoma in situ (CIN) 
in 7 patients. In 15 patients, an abnormal Pap smear was con-
firmed by histologic evaluation, and CIN was found in 11 (61.1%) 
of patients. Compared with the controls, SLE patients had a sig-
nificantly higher prevalence of high-risk HPV infections (24.6% 
vs. 7.9%, P<0.001, OR 3.8, 95% CI 2.5-5.7). The prevalence of ab-
normal cervical cytology was also increased in SLE patients 
compared with controls (16.4% vs. 2.8%, P<0.001, OR 4.4, 95% 
CI 2.5-7.8). 
Table 1. Demographic, social, reproductive, behavioral, and disease characteristics 
of SLE patients and controls
SLE (n=134) Control (n=4,595)
Demographic & social characteristics
   Age group, n (%)
       20-29 yr
       30-39 yr
       40-49 yr
       50-59 yr
       ≥60 yr
  20 (14.9)
  55 (41.0)
  40 (29.9)
  15 (11.2)
  4 (3.0)
  148 (3.2)
†
    590 (12.8)
†
 1,796 (39.1)*
 1,542 (33.5)
†
    519 (11.4)*
   Education, n (%)
       ≤12 yr
       >12 yr
  45 (33.6)
  89 (66.4)
NA
NA
   Smoker, n (%)   7 (5.2)  231 (5.0)
Reproductive & behavioral characteristics
   Parity, n (%)
       0
       1
       2
       ≥3
  29 (22.8)
  27 (21.3)
  58 (45.7)
  13 (10.2)
  249 (5.4)
†
    611 (13.3)*
 2,419 (52.7)*
 1,316 (28.6)
†
   Age at first intercourse, mean±SD, yr 23.9±4.0 NA
   Number of sexual partners, n (%)
       1
       2
       ≥3
109 (85.8)
10 (7.9)
  8 (6.3)
3,883 (84.5)
   457 (10.0)
 250 (5.5) 
   History of STD, n (%)   3 (2.2) NA
Disease characteristics
   Disease duration, mean±SD, months 51.2±43.2 -
   Major organ involvement, n (%) 89 (66.4) -
   Number of involved major organ, n (%)
       0
       1
       ≥2
  46 (34.3)
  62 (46.3)
  26 (19.4)
-
-
-
   Drugs ever used in treatment, n (%)
       Prednisolone ≤20 mg/day
       Prednisolone ≥1 mg/kg/day
       Hydroxychloroquine
       Azathioprine 
       Cyclosporine   
       Mycophenolate mofetil 
       Cyclophosphamide
128 (95.5)
104 (75.9)
  79 (56.9)
109 (79.6)
42 (30.7)
  15 (10.9)
  15 (10.9)
  41 (29.9)
-
-
-
-
-
-
-
-
   Immunosuppressive therapy, n (%)   97 (72.4) -
   Antinuclear antibody titer, mean±SD 1: 360±240 -
   Anti-dsDNA positivity, n (%)   92 (68.7) -
   Anti-dsDNA titer, mean±SD, IU/mL       62.5±139.8 -
   SLEDAI, mean±SD     8.1±6.4 -
*P<0.05; 
†P<0.001.
NA, not available; SLE, systemic lupus erythematosus; STD, sexually transmitted 
disease; SLEDAI, systemic lupus erythematosus disease activity index. Lee Y-H, et al.  •  HPV Infections in Korean SLE Patients
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Risk factors for development of high risk HPV infection 
Using univariate analysis, high risk HPV infection was associat-
ed with history of SLE (OR 3.8, 95% CI 2.5-5.7), multiple sexual 
partners (2: OR 7.2, 95% CI 5.4-9.5; ≥3: OR 3.4, 95% CI 2.4-5.0), 
and abnormal Pap smear (OR 18.9, 95% CI 11.0-32.6). Smoking 
and parity were not associated with high risk HPV infection 
(Table 2). Potential risk factors identified by univariate analysis 
(history of SLE, multiple sexual partners, abnormal Pap smear) 
including age were put into a multivariate model to identify in-
dependent risk factors for high risk HPV infection. Independent 
risk factors for high risk HPV infection included a history of SLE 
(OR 6.9, 95% CI 2.5-18.9), ≥2 sexual partners (OR 8.5, 95% CI 
1.2-61.6), and Pap smear abnormalities (OR 97.3, 95% CI 6.5-
1456.7) (Table 3).
Disease related risk factors for high risk HPV infection  
in SLE patients
High risk HPV positive and negative SLE patients were compar-
ed to determine the possible disease related risk factors for high 
risk HPV infection in SLE patients (Table 4). Odds ratios adjust-
ed for age, education, smoking, parity, number of sexual part-
ners, age at first intercourse, and history of sexually transmitted 
diseases were determined by multiple logistic regression analy-
sis. Significant increases in the number of patients with major 
organ involvement and the use of azathioprine were found in 
the high risk HPV positive SLE patients compared to the high 
risk SLE negative patients. However, adjusted odds ratios for 
these factors were not increased, thus not identified as a disease 
related risk factors for high risk HPV infection. No significant 
differences were found in the use of immunosuppressive agents 
ever, and the disease duration between patients with high risk 
HPV infection and those without (Table 4). 
DISCUSSION
Our study suggests that Korean patients with SLE have a signifi-
cantly increased prevalence of high-risk HPV infection and ab-
normal cervical cytology compared to controls. SLE itself ap-
pears to be the major risk factor for HPV infection. 
  Increased prevalence of HPV infection has been reported for 
small groups of SLE patients. In a study of 30 SLE patients by 
Nath et al. (8) from the United Kingdom, tests for high risk gen-
otype HPV-16 was positive in 57% of SLE patients compared to 
1% of controls. A study from of 85 SLE patients from China re-
vealed intermediate- or high-risk HPV genotype infection in 
10.6% of SLE patients versus 4.2% in controls (9). In a French 
study consisted of 11 women with SLE, HPV-positivity was ob-
served in 37.5% of the patients compared to 14.7% of the con-
trols (13). We observed that 24.6% of the 134 Korean SLE pa-
tients were infected with high-risk HPV. This represents 3.8 fold 
Table 2. Unadjusted odds ratio for potential risk factors associated with high risk HPV 
infection
No. of  
subjects
HPV positivity
Prevalence (%)
Unadjusted OR 
(95% CI)
History of SLE
   Yes
   No
134
4,595
24.6 (33/134)
7.9 (362/4,595)
3.8 (2.5-5.7)
1
Smoking
   Yes
   No
238
4,488
12.6 (30/238)
8.1 (365/4,488)
0.6 (0.4-0.9)
1
Parity
   0
   1
   2
   ≥3
278
638
2,477
1,329
33.8 (94/278)
19.6 (125/638)
14.3 (353/2,477)
13.9 (185/1,329)
1
0.3 (0.2-0.5)
0.7 (0.5-0.9)
1.0 (0.8-1.3)
No. of sexual partners
   1
   2
   ≥3
3,992
467
263
14.1 (561/3,992)
27.6 (129/467)
52.1 (124/238)
0.6 (0.1-9.1)
7.2 (5.4-9.5)
3.4 (2.4-5.0)
Abnormal PAP smear
   Yes
   No
149
4,580
45.6 (68/149)
7.1 (327/4,580)
18.9 (11.0-32.6)
1
Table 3. Odds ratios (95% confidence interval) determined by multiple logistic reg-
ression model using high risk HPV infection status as a variable
P Adjusted OR (95% CI)
History of SLE 0.001 6.9 (2.5-18.9)
Abnormal PAP smear 0.001   97.3 (6.5-1456.7)
≥2 sexual partners  0.035 8.5 (1.2-61.6)
Table 4. Disease related risk factors for high risk HPV infection in SLE patients*
HPV (+) SLE 
n=33 (%)
HPV (-) SLE 
n=101 (%)
P OR (CI)
Disease duration, months
   0-24 
   25-48
   49-72
   ≥73
12 (36.3)
  6 (18.2)
  6 (18.2)
  9 (27.3)
37 (36.6)
16 (15.8)
14 (13.9)
34 (33.7)
-
0.81
0.69
0.79
1.0
  0.78  
(0.11-5.52)
  0.44  
(0.06-3.15)
  1.25  
(0.24-6.53)
Major organ involvement 
   0
   1 major organ involvement
   ≥2 major organ involvement
10 (30.3)
11 (33.3)
12 (36.4)
35 (34.7)
52 (51.5)
14 (13.9)
-
0.03
0.01
1.0
  0.12
(0.02-0.85)
  0.04
(0.01-0.52)
Immunosuppressive therapy, 
   Ever
21 (63.6) 76 (75.2) 0.28   4.83 
(0.27-85.90)
   Prednisolone >1 mg/kg/day 16 (48.5) 60 (59.4) 0.38   0.39
(0.45-3.26)
   Azathioprine 11 (33.3) 31 (30.7) 0.04   0.15
(0.02-0.90)
   Cyclosporine 3 (9.1) 12 (11.9) 0.81   0.73
(0.06-9.15)
   Mycophenolate mofetil   4 (12.1) 11 (10.9) 0.20   4.69 
(0.43-50.86)
   Cyclophosphamide   7 (21.2) 33 (32.7) 0.41   2.35
(0.31-17.63)
*Values are the number (%) of patients.
HPV, human papillomavirus; SLE, systemic lupus erythematosus.Lee Y-H, et al.  •  HPV Infections in Korean SLE Patients
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increases in the prevalence of high-risk HPV in Korean SLE pa-
tients compared to the general population. Our data confirmed 
the previous observation in other ethnic group that SLE patients 
were more prone to HPV infection. 
  The major risk factor for acquisition of HPV infection is high-
risk sexual behavior (14). In this regard, the highest prevalence 
of HPV infection in the general population was noted in sexual-
ly active women of 20-24 yr of age, and those with multiple life-
time sexual partners (15). We also found that women with 2 or 
more sexual partners were 8.5 folds more at risk of acquiring 
high risk HPV infection. In turn, infection with high risk HPV 
increased the risk of developing abnormal cytology approxi-
mately 100 folds. However, other risk factor previously shown to 
be associated with HPV infection, cigarette smoking was not 
associated in our study. This may be due to much lower rate of 
cigarette smoking in our study population compared to other 
studies (9, 14). In addition to the external factors such as sexual 
behavior and cigarette smoking, host factor such as immuno-
compromised status as in SLE patients, can play a role in the 
perpetuation of HPV infection. 
  The possible mechanism for progression of HPV infection, 
from acquisition to development of cervical dysplasia, is incom-
pletely understood in immunocompromised host such as pa-
tients with SLE. However, it can be speculated that multiple de-
rangements of the immune system found in SLE can alter the 
natural course of the cervicovaginal infection to a more persis-
tent and recurrent infection. Immune derangements in SLE pa-
tients include activated humoral immunity, ineffective cell-me-
diated immunity, and a shift in balance from Th1 to Th2 cyto-
kines (16-18). In healthy individuals, T helper type 1 cells pro-
duce immunoregulatory cytokines that increase tumor immu-
nity (19). Therefore, CD4+ cells infiltrating the cervical epitheli-
um can induce regression of low-grade cervical lesions caused 
by low-risk HPV infection. In the general population, 70% of 
HPV infections are short-lived and spontaneously resolve in 
less than 1 yr due to effective viral clearance, especially in indi-
viduals under 30 yr of age (20). In cases of ineffective cytotoxici-
ty performed by CD8+ T cells (17) or a shift in the balance of Th1 
to Th2 cytokines (16) as seen in SLE, inefficient clearance of HPV 
occurs, resulting in the persistence of infection. Recurrent and 
persistent HPV infection has been shown to occur in patients 
with SLE (8, 9). Our observation that significantly increased num-
ber of patients with major organ involvement was found in the 
high risk HPV positive SLE patients compared to the HPV nega-
tive SLE patients suggests that the severity of the immune dys-
regulation of the host contributes to the increased susceptibility 
of SLE patients to HPV infection. However, due to small num-
ber of patients analyzed, risk for HPV infection was not increased 
in SLE patients with major organ involvement. 
  Immunosuppressive drugs used to treat the disease can be 
another risk factor for HPV infection in SLE patients. Immuno-
suppressive drugs can directly induce oncogenic cellular muta-
tion or result in ineffective immune protection against oncogen-
ic infection (7). Almost all studies to date reported increases in 
cervical dysplasia related to immunosuppressive drug use (21-
23). In the one study reporting no differences, there was a fail-
ure to control concurrently for important clinical variables (9). 
We did not find a difference in HPV positivity between patients 
treated with or without immunosuppressive therapy, although 
use of azathioprine was more common in the high risk HPV pos-
itive SLE patients. We did not find increased risk for high risk 
HPV infection related to the immunosuppressive drug use in 
the SLE patients. This may be due to the small number of the 
patients analyzed, or may be related to low sexual activity in ac-
tive severe SLE patients, which may decrease the chance of HPV 
infection by sexual intercourse. 
  The importance of high risk HPV infection is that it is the most 
important, and a requisite factor for development of cervical 
cancer, although other factors such as smoking, diet, cervical 
trauma, HIV co-infection and sexually transmitted infections 
may also contribute (24). Cervical cancer is still one of the lead-
ing causes of death worldwide and half a million of cervical can-
cers are attributable to HPV infection (25). The significance of 
HPV infection in SLE patients is greater since most SLE patients 
are women (10), and they are highly susceptible to become in-
fected with high risk, oncogenic HPV types due to the immuno-
compromised state of the host, which in turn, lead to cervical 
cancer (8, 9). The prevalence of abnormal cervical cytology in 
SLE patients was reported to be much greater than that in the 
general population (9, 26). We found that cervical cytological 
abnormalities were increased to 16.4% in SLE patients compar-
ed to 2.8% in the general population. 
  The incidence of cervical cancer has decreased significantly 
because of the availability of screening tests for cervical cytolo-
gy combined with HPV tests. The United States recommenda-
tions state that high-risk HPV test should be done every 3 yr for 
immuno-competent women over 30 yr of age with no past his-
tory of dysplasia (27). In Korea, current screening for cervical 
cancer in the general population only includes yearly Pap smears 
in females with a coitus history (28). However, development of 
guidelines including HPV testing in cervical cancer screening is 
currently under discussion. In addition, recent availability of 
HPV vaccines marked an important milestone in efforts to pre-
vent cervical cancer (29, 30). With these efforts, cervical cancer 
has become one of the preventable cancers. Since result of our 
study in accordance with the others alerts the medical commu-
nity of increased risk of cervical cancer in SLE patients, more 
stringent criteria should be applied to cervical cancer screening 
in SLE patients. To achieve this goal, studies examining cost effec-
tiveness of the screening procedure, and efficacy of HPV vacci-
nation in SLE patients should be conducted. 
  Our study is not without limitations. Because our compari-Lee Y-H, et al.  •  HPV Infections in Korean SLE Patients
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son sample comes from a different baseline general population 
in regards to regional residence, sexual activity and volunteer 
bias for low socioeconomic group, these differences might have 
introduced somewhat biased results. Cross-sectional studies 
possess limitations compared to prospective studies in evaluat-
ing the incidence and the time course of development of HPV 
infections. However, the strength of this study includes the de-
tailed evaluations of HPV status in a relatively large number of 
SLE patients. Age and region-matched prospective case-control 
study will provide more detailed information about risk factors 
for HPV infection in Korean SLE patients. 
  High-risk HPV infection and abnormal cervical cytology are 
more prevalent in Korean female patients with SLE compared 
with the controls. SLE itself appears to be a risk factor for HPV 
infection in Korean women. Based on our observations, close 
monitoring of HPV infections and abnormal PAP smears are 
recommended for immune-compromised individuals with SLE. 
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